James Maitland, a distinguished expert in healthcare market dynamics and medical technology, has spent years analyzing the intricate web of pharmacy benefit managers, manufacturers, and regulatory shifts. His work focuses on how technological and legislative changes can dismantle the opaque structures that have historically inflated the costs of care. Today, he joins us to discuss the seismic shifts triggered by the Consolidated Appropriations Act of 2026 and what this means for the future of drug pricing.
With new regulations limiting how pharmacy benefit managers earn profit from list prices, how do you expect drugmakers to justify their pricing strategies? What internal metrics or value-based data points will manufacturers need to prioritize to survive this shift in public and regulatory attention?
The legislative pendulum is swinging back toward the drugmakers with a force we haven’t seen in over a decade, effectively ending the era where manufacturers could hide behind PBM-driven inflation. For years, the industry relied on a paradigm where high list prices were essentially a currency used to buy PBM favor through rebates, but that excuse is being stripped away. To survive this shift, drugmakers must pivot toward rigorous clinical outcomes and real-world evidence as their primary justification for cost. We are going to see a massive internal push for metrics that demonstrate “true value,” such as quality-adjusted life years and comparative efficacy data, because the public will no longer accept the “rebate trap” as a reason for high prices. If a manufacturer keeps a list price high without the pressure of a PBM demanding a kickback, they will find themselves standing alone in a very bright, very uncomfortable spotlight.
PBMs must pass 100% of rebates and fees to plan sponsors by mid-2028. How will this requirement fundamentally change negotiation tactics between drugmakers and PBMs? What specific challenges do you foresee in transitioning from percentage-based fees to flat-rate, fair-market-value service fees?
The deadline of August 3, 2028, marks a total restructuring of the financial plumbing that connects manufacturers and PBMs. Currently, these parties negotiate not just on net price, but on a convoluted array of administrative, data, and formulary placement fees often tied to the drug’s list price. Transitioning to a flat-rate, fair-market-value system removes the perverse incentive to hike prices just to generate a larger percentage-based fee. The challenge lies in defining what a “bona fide” service fee actually looks like in a market that has never had to be transparent about these costs. It’s going to be a tense negotiation period as manufacturers try to determine what concessions they are willing to make when the old incentives for PBMs—churning out billions in profit through price-linked fees—are legally prohibited.
The CMS now has significant funding to audit supply chain fees and arbitrate disputes. What practical steps should organizations take to ensure compliance with these new auditing standards? How might this increased federal oversight alter the day-to-day administrative relationships between pharmacies, PBMs, and manufacturers?
With nearly $190 million in new funding, the CMS is no longer just a spectator; it has been given “sharper teeth” to enforce compliance and arbitrate long-standing disputes between pharmacies and PBMs. Organizations need to immediately standardize their data reporting and ensure that every service fee is defensible under fair-market-value audits. This federal oversight will likely cool the “blame game” between stakeholders, as there will now be a government arbiter looking at the actual contracts and flow of money. We should expect a more rigid, administrative relationship where every transaction is documented with the expectation that an auditor will eventually review it. It replaces the “handshake and a kickback” culture with a strict, compliance-first environment that prioritizes the 100% pass-through requirement.
Historically, list prices were often inflated to accommodate high rebates. Without these financial incentives, what is the step-by-step process for a market-wide “reset” on drug costs? How will the elimination of the “rebate trap” influence the initial launch pricing of upcoming breakthrough therapies?
The market reset will likely begin with manufacturers restructuring their PBM contracts to strip out any fees tethered to list prices or percentages. Step one is the decoupling of PBM profit from the drug’s price tag, which removes the “excuse” for artificial inflation that has plagued the industry for 20-plus years. For breakthrough therapies, this means the initial launch price should, in theory, be closer to the actual net price rather than an inflated figure meant to leave room for massive rebates. This creates a “rational drug pricing paradigm” where competition is based on the therapeutic value and the actual cost of innovation rather than the size of the discount offered to a middleman. It forces a return to fundamentals where a drug’s price must stand on its own merits in a transparent market.
Federal laws are moving toward value-based negotiated prices rather than list-price-driven models. In what ways will the interaction between these new PBM restrictions and existing drug negotiation laws redefine competition? How should manufacturers restructure their PBM contracts today to prepare for this future environment?
The synergy between the new PBM reforms and the Inflation Reduction Act is designed to dismantle the old financial framework and replace it with negotiated prices based on actual value. Competition will shift from “who can provide the biggest rebate” to “who can provide the most effective treatment at the best price,” which is how a healthy market should function. Manufacturers need to act now by defining what their service agreements will look like after the initial run-out period, ensuring no fees vary based on the drug’s cost. This proactive restructuring is essential because once these laws kick in, any manufacturer still clinging to the old percentage-based model will be facing both legal risks and a total loss of bargaining power. We are moving toward a world where the net price is the only price that matters.
What is your forecast for drug pricing transparency?
I believe we are entering an era of unprecedented visibility where the “black box” of drug pricing is finally being dismantled by federal law. Within the next four years, the elimination of the rebate trap will force a market reset that brings list prices into closer alignment with net prices, saving plan sponsors and patients from the hidden costs of intermediaries. My forecast is that by 2028, the industry will have transitioned to a flat-fee service model where every dollar in the supply chain is audited and accounted for. This transparency will not only lower out-of-pocket costs for many but will also force pharmaceutical companies to compete on the actual clinical value of their products rather than their ability to manipulate financial incentives. It is a painful transition for those who profited from the shadows, but it is a necessary evolution for a sustainable healthcare system.
